{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-001905","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.387629+00:00","generated_at":"2026-06-07T01:13:21.398471+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AIM ImmunoTech opens enrollment in Phase 1b/2 trial of Ampligen + Imfinzi for pancreatic cancer","bullets":["Enrollment open at Erasmus MC for DURIPANC study combining Ampligen + AstraZeneca's Imfinzi; dosing expected soon.","Phase 1b portion will enroll up to 18 subjects; Phase 2 up to 25 patients with metastatic pancreatic ductal adenocarcinoma.","Ampligen dose escalation from 200 mg to 400 mg IV twice weekly; durvalumab 1500 mg IV every 4 weeks for up to 48 weeks.","Primary objectives: safety in Phase 1b, clinical benefit rate in Phase 2.","AIM recently received a U.S. patent for using Ampligen in combination with an anti-PD-L1 antibody."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-001905","json":"https://secwatch.observer/filing/0001493152-24-001905.json","markdown":"https://secwatch.observer/filing/0001493152-24-001905.md","text":"https://secwatch.observer/filing/0001493152-24-001905.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315224001905/0001493152-24-001905-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315224001905/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:13:21.398471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}